The Power of Truth® has been released for sale and assignment to a conservative pro-American news outlet, cable network, or other media outlet that wants to define and brand its operation as the bearer of the truth, and set itself above the competition.

In every news story the audience hears of censorship, speech, and the truth. The Power of Truth® has significant value to define an outlet, and expand its audience. A growing media outlet may decide to rebrand their operation The Power of Truth®. An established outlet may choose to make it the slogan distinguishing their operation from the competition. You want people to think of your outlet when they hear it, and think of the slogan when they see your company name. It is the thing which answers the consumer's questions: Why should I choose you? Why should I listen to you? Think:

  • What’s in your wallet -- Capital One
  • The most trusted name in news – CNN
  • Fair and balanced - Fox News
  • Where’s the beef -- Wendy’s
  • You’re in good hands -- Allstate
  • The ultimate driving machine -- BMW

The Power of Truth® is registered at the federal trademark level in all applicable trademark classes, and the sale and assignment includes the applicable domain names. The buyer will have both the trademark and the domains so that it will control its business landscape without downrange interference.

Contact: Truth@ThePowerOfTruth.com

Weekly_031424 - cocoa

Human Interest

Reuters exclusively reported[1] that major African cocoa plants in Ivory Coast and Ghana have stopped or cut processing because they cannot afford to buy beans, meaning chocolate prices around the world are likely to soar. 

Market Impact

Read more

Weekly_031424 - Goldman

Business & Finance

Reuters exclusively reported[1] that Goldman Sachs Asset Management, a unit of Goldman Sachs Group, aims to expand its private credit portfolio to $300 billion in five years from the current $130 billion. 

Market Impact

Goldman Sachs

Read more

Flash_031124 - Novo

Business & FinanceHealth

Reuters was first to report[1] on the early trial data for Novo Nordisk’s highly anticipated experimental drug amycretin which showed that participants had a weight loss of 13.1% after 12 weeks, prompting the company’s shares

Read more

More Articles …